adyus
31st August 2005, 08:55 PM
A different topical for the treatment of rosacea...
http://www.drugresearcher.com/news/news-ng.asp?n=62216-photomedex-copper-peptide-skin-disorders
From patent 6,927,206:
"The utility of the composition of Example 7 was demonstrated in a 12 week study involving 8 human patients. More specifically, the cream of Example 7, containing glycyl-L-histidyl-L-lysine:copper(II), was tested for its effect on rosacea. The cream was applied as a thin film to the face twice each day, once in the morning and once at night.
At the beginning of the study, and at weeks 6 and 12, the number of inflammatory lesions (papules and pustules) was determined at the beginning of the study, and at weeks 6 and 12. In addition, the overall signs of rosacea were rated during the 12 week study using the following global assessment scale.
Rosacea Global Score:
0=Clear: absence of inflammatory sessions, erythema, and telangiectasias
1=Almost clear: absence of inflammatory lesions, or presence of a few small involuted lesions, trace of erythema, presence or absence of telangiectasias.
2=Mild: few small inflammatory lesions, mild erythema and presence or absence of telangiectasias.
3=Moderate: Moderate number of inflammatory lesions, moderate to severe erythema, presence of telangiectasias.
4=Severe: large number of inflammatory lesions, moderate to severe erythema, presence of telangiectasias.
The results of the evaluation are shown below for each of the 8 patients enrolled in the study. As shown, application of the cream of Example 7 reduced the total number of lesions for 5 of the 8 patients (63%) treated. The average reduction of lesions for the 5 patients showing an effect was 70%. The overall reduction of lesions for all 8 patients treated was 26%.
In a similar manner, 4 of the 8 patients showed a 50% decrease in the Rosacea Global Score, going from the "mild" to the "almost clear" category within the 12 week study period, thereby, indicating a response to the peptide copper treatment during that period. "
Adrian
http://www.drugresearcher.com/news/news-ng.asp?n=62216-photomedex-copper-peptide-skin-disorders
From patent 6,927,206:
"The utility of the composition of Example 7 was demonstrated in a 12 week study involving 8 human patients. More specifically, the cream of Example 7, containing glycyl-L-histidyl-L-lysine:copper(II), was tested for its effect on rosacea. The cream was applied as a thin film to the face twice each day, once in the morning and once at night.
At the beginning of the study, and at weeks 6 and 12, the number of inflammatory lesions (papules and pustules) was determined at the beginning of the study, and at weeks 6 and 12. In addition, the overall signs of rosacea were rated during the 12 week study using the following global assessment scale.
Rosacea Global Score:
0=Clear: absence of inflammatory sessions, erythema, and telangiectasias
1=Almost clear: absence of inflammatory lesions, or presence of a few small involuted lesions, trace of erythema, presence or absence of telangiectasias.
2=Mild: few small inflammatory lesions, mild erythema and presence or absence of telangiectasias.
3=Moderate: Moderate number of inflammatory lesions, moderate to severe erythema, presence of telangiectasias.
4=Severe: large number of inflammatory lesions, moderate to severe erythema, presence of telangiectasias.
The results of the evaluation are shown below for each of the 8 patients enrolled in the study. As shown, application of the cream of Example 7 reduced the total number of lesions for 5 of the 8 patients (63%) treated. The average reduction of lesions for the 5 patients showing an effect was 70%. The overall reduction of lesions for all 8 patients treated was 26%.
In a similar manner, 4 of the 8 patients showed a 50% decrease in the Rosacea Global Score, going from the "mild" to the "almost clear" category within the 12 week study period, thereby, indicating a response to the peptide copper treatment during that period. "
Adrian